Compared with IFX, ADA tended to have longer time to reinduction (median 22 vs 37 months respectively, p = 0.07) and longer time from reinduction to objective reinduction failure (median 11 vs 21, p = 0.60), albeit the latter was non-significant. Post-reinduction, factors associated at least 12 months continuation on same anti-TNF included, for both ADA and IFX, no current IBD extra-intestinal

manifestation(s) OR 10.5, 95% CI [1.5,71.4](p = 0.01), no psychological comorbidity OR 6.7 [1.05, 42.4] (each p < 0.05), female sex OR 3.9 [0.8, 21.3](p = 0.1). Again, female sex was associated with continuation at 12 months post-induction for ADA (Fisher's exact, p < 0.04) but not for IFX (p = 0.65). Conversely, concurrent thiopurine was associated with continuation (at 12 m) for IFX (p < 0.05) but not for ADA (p = 0.3) PLX4032 price and there was a trend for prior bowel resection to be associated with continuation for IFX but no ADA (p = 0.06). Conclusions: Overall reinduction was very effective in regaining response to anti-TNF in many patients, and should be considered in patients as the next step where concomitant immunomodulators have already been added. Smoking rates are high in this cohort, implying its important role

in secondary LOR. Pharmacokinetic find more differences between ADA and IFX, with the potentially greater immunogenic potential of IFX, may explain why concurrent learn more thiopurines were linked with more durable outcomes in IFX post-reinduction (but not ADA), and the differential response post-reinduction for ADA

between males and females. Further larger studies are needed in this area to best utilize anti-TNF reinduction to achieve optimal outcomes in the Australian PBS setting in CD. M OOI, J PANETTA, M ZHU, C CORTE, RWL LEONG Gastroenterology and Liver Services, Concord Hospital, Sydney Australia Background: Traditional forward-viewing colonoscopy (FVC) is impeded by a narrow field of view of <170 degrees with adenoma “miss-rates” of 24–42%. This limitation impairs dysplasia surveillance in chronic colitis. Chromoendoscopy improves visualization of dysplasia but has never been used with FUSE, which provides 330 degree visualization. This study compares FVC and FUSE with and without chromoendoscopy for the identification of dysplasia in IBD. Methods: This was a prospective, randomized-order, crossover tandem colonoscopy trial at an academic IBD center. Inclusion criteria were left sided or extensive colitis for >10 years disease duration, primary sclerosing cholangitis (PSC) or previous dysplasia. Patients underwent same-day, back-to-back tandem colonoscopy with FVC (PCF/CF 180/190, Olympus, Japan) and the FUSE colonoscope (EndoChoice, USA) under propofol sedation. Order randomization was computer-generated. Patients and endoscopist were masked to group allocation until immediately prior to colonoscopy.